Latest Publishing News

XPON Technologies (ASX: XPN) posted a $1.1 million positive EBITDA in FY26 on 38% revenue growth, shedding Alpha Digital and selling its Google Marketing business to focus on its Wondaris AI platform.

AUB Group delivered a robust FY26 with 12.2% underlying NPAT growth to $224.6 million, driven by strong international and domestic performances, and completed its strategic UK Prestige acquisition. The company declared a fully franked 71-cent final dividend and provided positive FY27 profit guidance.

NZME delivered a notable turnaround in the first half of 2026, doubling operating profit and cutting net debt by $13.9 million, led by strong audio revenue and digital expansion despite a challenging economic backdrop.

Symal Group (ASX: SYL) delivered record FY26 results, surpassing $1 billion in revenue and completing four strategic acquisitions to diversify its infrastructure services platform.

SenSen Networks has landed a $889,000 two-year contract with EPA Victoria to trial acoustic vehicle noise enforcement, marking its SenDISA platform's first foray into environmental regulation.

North Stawell Minerals has pushed its high-grade gold footprint at Darlington further north, intersecting 0.4m at 17.1 g/t Au over 70m beyond previous results, reinforcing the prospect’s likeness to the nearby Stawell Gold Mine.

SportsHero Limited has partnered with Carry1st to distribute gaming top-up vouchers and ePINs via its HeroPlay platform, adding major titles and platform vouchers to its Southeast Asian offering.

Streamplay’s Noodlecake Studios has deepened its collaboration with Butter By The Fish by signing a publishing deal for Monkey Brain, a physics-based roguelike, while also preparing Flick Shot Rogues for a mobile launch in September 2026.

Regis Healthcare reported a robust FY26 with revenue hitting $1.35 billion, underpinned by strong occupancy and strategic acquisitions. The company is investing heavily in growth and digital transformation while navigating sector reforms and climate risks.

Cyclopharm Limited posted a fifth consecutive record half-year revenue of $17.5 million, propelled by a 74% jump in US Technegas® sales and a doubling of revenue-generating US sites. New US clinical guidelines naming Technegas® as the preferred ventilation imaging agent underpin a robust growth outlook despite a wider net loss.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Noumi Limited lifted FY26 revenue by 8.8% and adjusted operating EBITDA by 7.6%, driven by Dairy & Nutritionals' strong earnings and strategic investments in Plant-based Milks. The company faces refinancing uncertainty with $610 million convertible notes maturing in May 2027, prompting a proposed acquisition by majority shareholder Arrovest.